The immune system has a role in almost every disease, from infections and cancers to Alzheimer’s, and is even important for normal childhood development. Drugs that modulate the immune system are revolutionizing the treatment of numerous diseases, including arthritis, inflammatory bowel disease, and lung cancer. The scope of this emerging medical revolution requires a new commitment to basic and clinical immunology research that will lead to new immune diagnostics and therapeutics, and uncover the genetic and environmental triggers of immune and inflammatory diseases.
To meet these goals, Mount Sinai has established the Precision Immunology Institute at the Icahn School of Medicine (PrIISM), a new entity that encompasses and integrates disease-focused immunological research programs and cutting-edge technology centers. PrIISM is working to better understand the fundamental mechanisms used by immune cells to promote disease progression and response to treatment, developing and implementing novel technologies to better diagnose and guide treatment of disease, and generating new therapies to modulate the immune system in broad spectrum of diseases, including cancer.
The PrIISM faculty focus on diverse area of medicine including Cancer, Immunodefiencies, Mucosal and Skin Immunity, Infectious Disease, Inflammatory Bowel Diseases, Lung and Vascular immunology, Type I Diabetes, Neurodegenerative and Neuroinflammatory Diseases, Allergy and Transplantation.
The Precision Immunology Institute at the Icahn School of Medicine holds two types of conferences, Seminars and Works in Progress.